NorthWest Biotherapeutics Inc (NWBO)

[dennisdave]

Yes, an ASM was due this year but that has nothing to do with needing to raise the authorized shares by nearly a billion. You don’t increase A/S by 900M shares “just in case” or “to avoid a mess.” Companies only do that when they expect continued dilution before a major catalyst, not after it.

And the idea that NWBO “must” raise A/S because they “don’t know what MHRA is waiting for” is backwards. If they were anywhere near approval, they would not pre-emptively increase the authorization. They would wait, because approval itself changes their entire financing landscape. The fact that they are raising A/S before MHRA clarity tells you exactly what the company knows internally: the timeline is not close, and they need runway for whatever CMC work remains.

Also, if a third-party agreement depends on approval, you don’t need more authorized shares now because such a deal only triggers after approval, when the stock is much higher and dilution is far less of an issue. So no this isn’t administrative housekeeping. It’s a signal that financing will be required while the MHRA timeline remains uncertain, which is only the case if CMC expansion (likely Flaskworks/Eden) is still in review.